Evidence map›Paper›PMID 29947961›Full record

ReviewCancer immunology, immunotherapy : CII2019

Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter.

Roberto Ruiu, Valeria Rolih, Elisabetta Bolli, Giuseppina Barutello, Federica Riccardo, Elena Quaglino, Irene Fiore Merighi, Federica Pericle, Gaetano Donofrio, Federica Cavallo and 1 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Gain of Function (GOF) Mutant p53 in Cancer-Current Therapeutic Approaches.International journal of molecular sciences · 2022
    Review
  12. Article
  13. Review
  14. Review
  15. System XFrontiers in pharmacology · 2022
    Review
  16. Article
  17. System XcInvestigational new drugs · 2021
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Roberto RuiuDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Via Nizza, 52, 10126, Turin, Italy.
Valeria RolihDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Via Nizza, 52, 10126, Turin, Italy.
Elisabetta BolliDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Via Nizza, 52, 10126, Turin, Italy.
Giuseppina BarutelloDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Via Nizza, 52, 10126, Turin, Italy.
Federica RiccardoDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Via Nizza, 52, 10126, Turin, Italy.
Elena QuaglinoDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Via Nizza, 52, 10126, Turin, Italy.
Irene Fiore MerighiDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Via Nizza, 52, 10126, Turin, Italy.
Federica PericleAgilvax, Inc, Albuquerque, NM, USA.
Gaetano DonofrioDepartment of Medical Veterinary Science, University of Parma, Parma, Italy.
Federica CavalloDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Via Nizza, 52, 10126, Turin, Italy.ORCID http://orcid.org/0000-0003-4571-1060
Laura ContiDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Via Nizza, 52, 10126, Turin, Italy.
University of Turin · ITUniversity of Parma · IT

Funding

Associazione Italiana per la Ricerca sul Cancro IG 11675
6 · The paper itself

Abstract

Tumor relapse and metastatic spreading act as major hindrances to achieve complete cure of breast cancer. Evidence suggests that cancer stem cells (CSC) would function as a reservoir for the local and distant recurrence of the disease, due to their resistance to radio- and chemotherapy and their ability to regenerate the tumor. Therefore, the identification of appropriate molecular targets expressed by CSC may be critical in the development of more effective therapies. Our studies focused on the identification of mammary CSC antigens and on the development of CSC-targeting vaccines. We compared the transcriptional profile of CSC-enriched tumorspheres from an Her2

Indexed as

Amino Acid Transport System y+AnimalsBreast NeoplasmsCancer VaccinesCell Line, TumorFemaleHumansMammary Neoplasms, ExperimentalMice, Inbred BALB CNeoplastic Stem CellsAmino Acid Transport System y+Cancer VaccinesSLC7A11 protein, humanBreast cancerCancer stem cellNIBIT 2017TumorsphereVaccinexCT

Identifiers

PMID29947961
PMCPMC11028170
OpenAlexW2807723055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.